Bioavailability and Bioequivalence Studies


Bioavailability means the rate and extent to which the active drug substance or therapeutic moiety is absorbed from a pharmaceutical form and becomes available at the site of action. For drugs intended to exhibit a systemic therapeutic effect, bioavailability can be more simply understood as the rate and extent to which a substance or its therapeutic moiety is delivered from a pharmaceutical form into the general circulation. Bioequivalence focus on the release of a drug substance from a drug product and subsequent absorption into systemic circulation. Bioequivalence studies are a surrogate marker for clinical effectiveness and safety data as it would not normally be practical to repeat clinical studies for generic products.


    Related Conference of Bioavailability and Bioequivalence Studies

    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    July 25-26, 2024

    34th Annual European Pharma Congress

    Zurich, Switzerland
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 28-29, 2024

    39th World Congress on Pharmacology and Therapeutics

    Paris, France
    December 05-06, 2024

    17th World Drug Delivery Summit

    Dubai, UAE

    Bioavailability and Bioequivalence Studies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in